-
1
-
-
43449108927
-
-
Aliskiren. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
-
Aliskiren. US Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2007.
-
(2007)
US Prescribing Information
-
-
-
2
-
-
0042661157
-
Structure-based design of aliskiren, a novel orally effective renin inhibitor
-
Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, Ruger H, Goschke R, Stutz S, Fuhrer W et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003 308 : 698 705.
-
(2003)
Biochem Biophys Res Commun
, vol.308
, pp. 698-705
-
-
Wood, J.M.1
Maibaum, J.2
Rahuel, J.3
Grutter, M.G.4
Cohen, N.C.5
Rasetti, V.6
Ruger, H.7
Goschke, R.8
Stutz, S.9
Fuhrer, W.10
-
3
-
-
33947182655
-
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension
-
Oh B-H, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007 49 : 1157 1163.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1157-1163
-
-
Oh, B.-H.1
Mitchell, J.2
Herron, J.R.3
Chung, J.4
Khan, M.5
Keefe, D.L.6
-
4
-
-
14844363404
-
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients
-
Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005 111 : 1012 1018.
-
(2005)
Circulation
, vol.111
, pp. 1012-1018
-
-
Gradman, A.H.1
Schmieder, R.E.2
Lins, R.L.3
Nussberger, J.4
Chiang, Y.5
Bedigian, M.P.6
-
5
-
-
33845366982
-
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
-
Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007 25 : 217 226.
-
(2007)
J Hypertens
, vol.25
, pp. 217-226
-
-
Villamil, A.1
Chrysant, S.G.2
Calhoun, D.3
Schober, B.4
Hsu, H.5
Matrisciano-Dimichino, L.6
Zhang, J.7
-
6
-
-
38649102508
-
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
-
Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G, Fang H, Satlin A. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007 8 : 190 198.
-
(2007)
J Renin Angiotensin Aldosterone Syst
, vol.8
, pp. 190-198
-
-
Uresin, Y.1
Taylor, A.A.2
Kilo, C.3
Tschope, D.4
Santonastaso, M.5
Ibram, G.6
Fang, H.7
Satlin, A.8
-
7
-
-
36248931230
-
Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy
-
Drummond W, Munger MA, Essop MR, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007 9 : 742 750.
-
(2007)
J Clin Hypertens
, vol.9
, pp. 742-750
-
-
Drummond, W.1
Munger, M.A.2
Essop, M.R.3
Maboudian, M.4
Khan, M.5
Keefe, D.L.6
-
8
-
-
34447521458
-
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
-
Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007 370 : 221 229.
-
(2007)
Lancet
, vol.370
, pp. 221-229
-
-
Oparil, S.1
Yarows, S.A.2
Patel, S.3
Fang, H.4
Zhang, J.5
Satlin, A.6
-
9
-
-
33947223136
-
Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension
-
Sica D, Gradman AH, Lederballe O, Meyers M, Cai J, Keefe DL. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006 27 (Suppl. 121.
-
(2006)
Eur Heart J
, vol.27
, pp. 121
-
-
Sica, D.1
Gradman, A.H.2
Lederballe, O.3
Meyers, M.4
Cai, J.5
Keefe, D.L.6
-
10
-
-
39849089447
-
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial
-
Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial. J Hypertens 2008 26 : 589 599.
-
(2008)
J Hypertens
, vol.26
, pp. 589-599
-
-
Andersen, K.1
Weinberger, M.H.2
Egan, B.3
Constance, C.M.4
Ali, M.A.5
Jin, J.6
Keefe, D.L.7
-
11
-
-
34447621764
-
Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis
-
Weir MR, Bush C, Anderson DR, Zhang J, Keefe DL, Satlin A. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis. J Am Soc Hypertens 2007 1 : 264 277.
-
(2007)
J Am Soc Hypertens
, vol.1
, pp. 264-277
-
-
Weir, M.R.1
Bush, C.2
Anderson, D.R.3
Zhang, J.4
Keefe, D.L.5
Satlin, A.6
-
12
-
-
33749853955
-
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers
-
Vaidyanathan S, Valencia J, Kemp C, Zhao C, Yeh C-M, Bizot M-N, Denouel J, Dieterich H-A, Dole WP. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006 60 : 1343 1356.
-
(2006)
Int J Clin Pract
, vol.60
, pp. 1343-1356
-
-
Vaidyanathan, S.1
Valencia, J.2
Kemp, C.3
Zhao, C.4
Yeh, C.-M.5
Bizot, M.-N.6
Denouel, J.7
Dieterich, H.-A.8
Dole, W.P.9
-
13
-
-
53349090037
-
Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers
-
Huang H-LA, Vaidyanathan S, Yeh C-M, Bizot M-N, Dieterich H-A, Dole WP, Howard D. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers. Curr Med Res Opin 2008 24 : 2449 2456.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 2449-2456
-
-
H-La, H.1
Vaidyanathan, S.2
Yeh, C.-M.3
Bizot, M.-N.4
Dieterich, H.-A.5
Dole, W.P.6
Howard, D.7
-
14
-
-
28044453329
-
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine
-
Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005 43 : 527 535.
-
(2005)
Int J Clin Pharmacol Ther
, vol.43
, pp. 527-535
-
-
Dieterle, W.1
Corynen, S.2
Vaidyanathan, S.3
Mann, J.4
-
15
-
-
34547221695
-
Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers
-
Waldmeier FJ, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, Vaidyanathan S. Absorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007 35 : 1418 1428.
-
(2007)
Drug Metab Dispos
, vol.35
, pp. 1418-1428
-
-
Waldmeier, F.J.1
Glaenzel, U.2
Wirz, B.3
Oberer, L.4
Schmid, D.5
Seiberling, M.6
Valencia, J.7
Riviere, G.J.8
End, P.9
Vaidyanathan, S.10
-
16
-
-
28044468751
-
Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro
-
Vaidyanathan S, Jin Y, Schiller H, Jensen C. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res Pharmacol Toxicol 2005 97 (Suppl. 1 239.
-
(2005)
Basic Res Pharmacol Toxicol
, vol.97
, Issue.1
, pp. 239
-
-
Vaidyanathan, S.1
Jin, Y.2
Schiller, H.3
Jensen, C.4
-
17
-
-
33644789557
-
Renin inhibition with aliskiren: Where are we now, and where are we going?
-
Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: Where are we now, and where are we going? J Hypertens 2006 24 : 243 256.
-
(2006)
J Hypertens
, vol.24
, pp. 243-256
-
-
Azizi, M.1
Webb, R.2
Nussberger, J.3
Hollenberg, N.K.4
-
18
-
-
0025720085
-
A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers
-
Storm G, Oosterhuis B, Bron J, Wittebrood AJ, De Jong AP, Jonkman JH. A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers. Biopharm Drug Dispos 1991 12 : 661 672.
-
(1991)
Biopharm Drug Dispos
, vol.12
, pp. 661-672
-
-
Storm, G.1
Oosterhuis, B.2
Bron, J.3
Wittebrood, A.J.4
De Jong, A.P.5
Jonkman, J.H.6
-
19
-
-
33749850285
-
Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers
-
Dieterich H-A, Kemp C, Vaidyanathan S, Yeh C-M. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 2006 79 (Suppl. 64.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 64
-
-
Dieterich, H.-A.1
Kemp, C.2
Vaidyanathan, S.3
Yeh, C.-M.4
-
20
-
-
47049089844
-
Clinical pharmacokinetics and pharmacodynamics of aliskiren
-
Vaidyanathan S, Jarugula V, Dieterich H-A, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008 47 : 515 531.
-
(2008)
Clin Pharmacokinet
, vol.47
, pp. 515-531
-
-
Vaidyanathan, S.1
Jarugula, V.2
Dieterich, H.-A.3
Howard, D.4
Dole, W.P.5
-
21
-
-
0025238474
-
Furosemide (frusemide). a pharmacokinetic/pharmacodynamic review (Part I)
-
Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/ pharmacodynamic review (Part I). Clin Pharmacokinet 1990 18 : 381 408.
-
(1990)
Clin Pharmacokinet
, vol.18
, pp. 381-408
-
-
Ponto, L.L.1
Schoenwald, R.D.2
-
22
-
-
0020535325
-
Biotransformation of furosemide in kidney transplant patients
-
Smith DE, Benet LZ. Biotransformation of furosemide in kidney transplant patients. Eur J Clin Pharmacol 1983 24 : 787 790.
-
(1983)
Eur J Clin Pharmacol
, vol.24
, pp. 787-790
-
-
Smith, D.E.1
Benet, L.Z.2
-
23
-
-
0028874981
-
Extrahepatic metabolism of frusemide in anaesthetized rabbits
-
Verges J, Heroux L, Maurice H, du Souich P. Extrahepatic metabolism of frusemide in anaesthetized rabbits. Br J Pharmacol 1995 116 : 2407 2412.
-
(1995)
Br J Pharmacol
, vol.116
, pp. 2407-2412
-
-
Verges, J.1
Heroux, L.2
Maurice, H.3
Du Souich, P.4
-
24
-
-
0034072174
-
Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions
-
Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 2000 57 : 760 768.
-
(2000)
Mol Pharmacol
, vol.57
, pp. 760-768
-
-
Bakos, E.1
Evers, R.2
Sinko, E.3
Varadi, A.4
Borst, P.5
Sarkadi, B.6
-
25
-
-
47049093197
-
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans
-
Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008 117 : 3199 3205.
-
(2008)
Circulation
, vol.117
, pp. 3199-3205
-
-
Fisher, N.D.1
Jan Danser, A.H.2
Nussberger, J.3
Dole, W.P.4
Hollenberg, N.K.5
-
26
-
-
44949088665
-
Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics
-
Vallon V, Rieg T, Ahn SY, Wu W, Eraly SA, Nigam SK. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol 2008 294 : F867 873.
-
(2008)
Am J Physiol Renal Physiol
, vol.294
-
-
Vallon, V.1
Rieg, T.2
Ahn, S.Y.3
Wu, W.4
Eraly, S.A.5
Nigam, S.K.6
-
27
-
-
0023215206
-
Isosorbide 5-mononitrate pharmacokinetics
-
Chasseaud LF. Isosorbide 5-mononitrate pharmacokinetics. Cardiology 1987 74 (Suppl. 1 6 11.
-
(1987)
Cardiology
, vol.74
, Issue.1
, pp. 6-11
-
-
Chasseaud, L.F.1
-
28
-
-
34547628374
-
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment
-
Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D, Dole WP. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007 46 : 661 675.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 661-675
-
-
Vaidyanathan, S.1
Bigler, H.2
Yeh, C.3
Bizot, M.N.4
Dieterich, H.A.5
Howard, D.6
Dole, W.P.7
-
29
-
-
41149087776
-
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects
-
Ayalasomayajula S, Tchaloyan S, Yeh C-M, Bizot M-N, Dieterich H-A, Howard D, Dole WP. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. CMRO 2008 24 : 717 726.
-
(2008)
CMRO
, vol.24
, pp. 717-726
-
-
Ayalasomayajula, S.1
Tchaloyan, S.2
Yeh, C.-M.3
Bizot, M.-N.4
Dieterich, H.-A.5
Howard, D.6
Dole, W.P.7
-
30
-
-
0029074273
-
Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation
-
Kosoglou T, Patrick JE, Cohen A, Radwanski E, Christopher D, Affrime MB. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. Clin Ther 1995 17 : 241 251.
-
(1995)
Clin Ther
, vol.17
, pp. 241-251
-
-
Kosoglou, T.1
Patrick, J.E.2
Cohen, A.3
Radwanski, E.4
Christopher, D.5
Affrime, M.B.6
|